(Bay Area Study) Intermittent Fasting for Bipolar Disorder
Trial Summary
What is the purpose of this trial?
The goal of this clinical trial is to understand how level of adherence with time-restricted eating (TRE) predicts change in diurnal rhythms (as measured using the amplitude of diurnal peripheral clock gene expression), and how those changes predict lower mania and depressive symptoms, and downstream improvements in quality of life. The effects of diurnal amplitude of clock gene expression is expected to remain significant when controlling for change in glucose tolerance and inflammation. Participants will be enrolled who are already receiving medication treatment for bipolar disorder. Participants will complete daily measures of eating, sleep and mood for two weeks, and then will be assigned to follow TRE for eight weeks. Symptoms and Quality of Life will be measured at baseline and during and after the food plan.
Will I have to stop taking my current medications?
The trial does not specify if you need to stop taking your current medications, but it does require that your mood-stabilizing medication regimen has been stable for at least one month. Some medications, like clozapine and glucose-lowering medications, are not allowed if they are contraindicated for fasting.
What data supports the effectiveness of the treatment Time-restricted eating for Bipolar Disorder?
Is intermittent fasting safe for humans?
How does time-restricted eating differ from other treatments for bipolar disorder?
Time-restricted eating (TRE) is unique because it focuses on limiting food intake to specific hours of the day, which may help improve metabolic health and potentially influence mood disorders like bipolar disorder. Unlike traditional medications for bipolar disorder, TRE is a dietary approach that may also offer benefits for weight management and metabolic health.1241011
Research Team
Sheri L Johnson, PhD
Principal Investigator
University of California, Berkeley
Eligibility Criteria
This trial is for individuals with bipolar I or II disorder, who speak English and have been on a stable mood-stabilizing medication regimen for at least one month. They should not have had significant weight changes recently, eat over a 12-hour period regularly, and can use a phone camera and web surveys. People with sleep disorders or those doing shift work that disrupts sleep are excluded.Inclusion Criteria
Timeline
Screening
Participants are screened for eligibility to participate in the trial
Baseline
Participants complete baseline measures of eating, sleep, and mood for two weeks
Treatment
Participants follow time-restricted eating (TRE) for 8 weeks, with online psychoeducation and optional weekly coaching
Follow-up
Participants are monitored for changes in symptoms and quality of life post-intervention
Treatment Details
Interventions
- Time-restricted eating
Find a Clinic Near You
Who Is Running the Clinical Trial?
University of California, Berkeley
Lead Sponsor
Salk Institute for Biological Studies
Collaborator
University College, London
Collaborator
Wellcome Trust
Collaborator
Swinburne University of Technology
Collaborator
Deakin University
Collaborator
University of British Columbia
Collaborator